Cargando…

Assessment of antiphospholipid antibodies and calprotectin as biomarkers for discriminating mild from severe COVID‐19

BACKGROUND: To explore the association of thrombo‐inflammatory biomarkers with severity in coronavirus disease (COVID‐19), we measured antiphospholipid antibodies (aPL) and calprotectin in sera of COVID‐19 patients. METHODS: Anticardiolipin antibodies (aCL) and anti‐β2‐glycoprotein I antibodies were...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Anna, Nahm, Chung Hyun, Lee, Jin‐Soo, Lee, Mi‐Kyeong, Lee, Kyoung‐Ryul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605160/
https://www.ncbi.nlm.nih.gov/pubmed/34608677
http://dx.doi.org/10.1002/jcla.24004
_version_ 1784602116921229312
author Lee, Anna
Nahm, Chung Hyun
Lee, Jin‐Soo
Lee, Mi‐Kyeong
Lee, Kyoung‐Ryul
author_facet Lee, Anna
Nahm, Chung Hyun
Lee, Jin‐Soo
Lee, Mi‐Kyeong
Lee, Kyoung‐Ryul
author_sort Lee, Anna
collection PubMed
description BACKGROUND: To explore the association of thrombo‐inflammatory biomarkers with severity in coronavirus disease (COVID‐19), we measured antiphospholipid antibodies (aPL) and calprotectin in sera of COVID‐19 patients. METHODS: Anticardiolipin antibodies (aCL) and anti‐β2‐glycoprotein I antibodies were measured using enzyme‐linked immunosorbent assay (ELISA) and multiplex flow immunoassay (MFIA) in hospitalized COVID‐19 patients (N = 105) and healthy controls (N = 38). Anti‐phosphatidylserine/prothrombin antibodies, calprotectin, and C‐reactive protein (CRP) levels were also measured. We assessed the potential correlation between calprotectin levels and various laboratory parameters that were measured during the hospitalization period. After stratifying COVID‐19 patients into two groups by their oxygenation status or acute respiratory distress syndrome presentation, the discriminatory performance of each biomarker was evaluated. RESULTS: A high proportion of COVID‐19 patients (29.5%, 31/105) had low aCL IgM titers that were detectable by ELISA but mostly below the detection limit of MFIA. Calprotectin levels in severe groups of COVID‐19 were significantly higher than those in non‐severe groups, while CRP levels revealed no significant differences. Serum calprotectin levels showed strong to moderate degree of correlation with other routinely used parameters including peak levels of CRP, ferritin, procalcitonin, BUN, and neutrophil‐to‐lymphocyte ratio, but a negative correlation with minimal lymphocyte count and CD4(+) T cells. The discriminatory performance was highest for calprotectin in discriminating severe groups of COVID‐19. CONCLUSIONS: Serum calprotectin levels were significantly elevated in severe COVID‐19 cases. The prevalence of clinically significant aPL did not differ. The link between calprotectin and inflammatory pathway in COVID‐19 may help improve the management and outcomes of COVID‐19 patients.
format Online
Article
Text
id pubmed-8605160
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-86051602021-11-24 Assessment of antiphospholipid antibodies and calprotectin as biomarkers for discriminating mild from severe COVID‐19 Lee, Anna Nahm, Chung Hyun Lee, Jin‐Soo Lee, Mi‐Kyeong Lee, Kyoung‐Ryul J Clin Lab Anal Research Articles BACKGROUND: To explore the association of thrombo‐inflammatory biomarkers with severity in coronavirus disease (COVID‐19), we measured antiphospholipid antibodies (aPL) and calprotectin in sera of COVID‐19 patients. METHODS: Anticardiolipin antibodies (aCL) and anti‐β2‐glycoprotein I antibodies were measured using enzyme‐linked immunosorbent assay (ELISA) and multiplex flow immunoassay (MFIA) in hospitalized COVID‐19 patients (N = 105) and healthy controls (N = 38). Anti‐phosphatidylserine/prothrombin antibodies, calprotectin, and C‐reactive protein (CRP) levels were also measured. We assessed the potential correlation between calprotectin levels and various laboratory parameters that were measured during the hospitalization period. After stratifying COVID‐19 patients into two groups by their oxygenation status or acute respiratory distress syndrome presentation, the discriminatory performance of each biomarker was evaluated. RESULTS: A high proportion of COVID‐19 patients (29.5%, 31/105) had low aCL IgM titers that were detectable by ELISA but mostly below the detection limit of MFIA. Calprotectin levels in severe groups of COVID‐19 were significantly higher than those in non‐severe groups, while CRP levels revealed no significant differences. Serum calprotectin levels showed strong to moderate degree of correlation with other routinely used parameters including peak levels of CRP, ferritin, procalcitonin, BUN, and neutrophil‐to‐lymphocyte ratio, but a negative correlation with minimal lymphocyte count and CD4(+) T cells. The discriminatory performance was highest for calprotectin in discriminating severe groups of COVID‐19. CONCLUSIONS: Serum calprotectin levels were significantly elevated in severe COVID‐19 cases. The prevalence of clinically significant aPL did not differ. The link between calprotectin and inflammatory pathway in COVID‐19 may help improve the management and outcomes of COVID‐19 patients. John Wiley and Sons Inc. 2021-10-05 /pmc/articles/PMC8605160/ /pubmed/34608677 http://dx.doi.org/10.1002/jcla.24004 Text en © 2021 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research Articles
Lee, Anna
Nahm, Chung Hyun
Lee, Jin‐Soo
Lee, Mi‐Kyeong
Lee, Kyoung‐Ryul
Assessment of antiphospholipid antibodies and calprotectin as biomarkers for discriminating mild from severe COVID‐19
title Assessment of antiphospholipid antibodies and calprotectin as biomarkers for discriminating mild from severe COVID‐19
title_full Assessment of antiphospholipid antibodies and calprotectin as biomarkers for discriminating mild from severe COVID‐19
title_fullStr Assessment of antiphospholipid antibodies and calprotectin as biomarkers for discriminating mild from severe COVID‐19
title_full_unstemmed Assessment of antiphospholipid antibodies and calprotectin as biomarkers for discriminating mild from severe COVID‐19
title_short Assessment of antiphospholipid antibodies and calprotectin as biomarkers for discriminating mild from severe COVID‐19
title_sort assessment of antiphospholipid antibodies and calprotectin as biomarkers for discriminating mild from severe covid‐19
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605160/
https://www.ncbi.nlm.nih.gov/pubmed/34608677
http://dx.doi.org/10.1002/jcla.24004
work_keys_str_mv AT leeanna assessmentofantiphospholipidantibodiesandcalprotectinasbiomarkersfordiscriminatingmildfromseverecovid19
AT nahmchunghyun assessmentofantiphospholipidantibodiesandcalprotectinasbiomarkersfordiscriminatingmildfromseverecovid19
AT leejinsoo assessmentofantiphospholipidantibodiesandcalprotectinasbiomarkersfordiscriminatingmildfromseverecovid19
AT leemikyeong assessmentofantiphospholipidantibodiesandcalprotectinasbiomarkersfordiscriminatingmildfromseverecovid19
AT leekyoungryul assessmentofantiphospholipidantibodiesandcalprotectinasbiomarkersfordiscriminatingmildfromseverecovid19